Jefferies raised the firm’s price target on Quest Diagnostics (DGX) to $215 from $200 and keeps a Buy rating on the shares. Sales and EPS beat consensus and fiscal year guidance was raised, notes the analyst, who is “encouraged” by the organic acceleration and “optimistic” for the Haystack MRD test ramp in 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics price target raised to $210 from $203 at Leerink
- Morning Movers: General Motors and RTX higher following Q3 reports
- Quest Diagnostics: Strong Performance and Promising Outlook Justify Buy Rating
- Quest Diagnostics reports Q3 adjusted EPS $2.60, consensus $2.50
- Quest Diagnostics raises FY25 adjusted EPS view to $9.76-$9.84 from $9.63-$9.83